PHARMACYTE BIOTECH INC (PMCB)
US71715X2036 - Common Stock
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PharmaCyte Biotech (NASDAQ:PMCB) just reported results for the third quarter of...
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
PharmaCyte Biotech just reported results for the third quarter of 2024.
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
PharmaCyte Biotech just reported results for the second quarter of 2024.
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PharmaCyte Biotech (NASDAQ:PMCB) just reported results for the second quarter o...
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte stock completes tender offer to purchase shares
PharmaCyte Biotech (PMCB) announced Thursday the completion of its previously announced tender offer to purchase up to 7.8M shares of the common stock. Read more here.
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®...
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS
/PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a...
IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS
/PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc....
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING
/PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc....
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
